The Lankenau Institute for Medical Research
LIMR Professor Iraimoudi Ayene's recent paper in Toxicology in Vitro [26 (2012) 603-612] was chosen as a Key Scientific Article by Global Medical Discovery. The prominent research news website compiles the latest innovative discoveries in the scientific, medical, and pharmaceutical communities. Global Medical Discovery has recognized the scientific impact of the revolutionary method that Dr. Ayene has developed for quickly and accurately counting viable cells.
“Many researchers are limited in their ability to produce reliable cell survival results because current viability assays have a number of disadvantages,” states Dr. Ayene. “These include non-linear data, inconsistent results, insolubility and membrane impermeability of the active compound. Furthermore, most of these decades-old methods are expensive and time-consuming.” He has developed a novel test using a bioactive probe that does not have any of these issues. Dr. Ayene’s research has shown a direct correlation between bioactivation of this probe and cell survival/proliferation. This new way of measuring cell proliferation and survival is useful for drug discovery and toxicity tests after radiation, chemotherapeutics, and toxins.
LIMR Development, Inc. (LDI), the business subsidiary of Lankenau Institute for Medical Research, has commercialized Dr. Ayene’s work as CellCountEZ®, a cell toxicity, proliferation, and survival assay kit. The bioactive probe in CellCountEZ® is better than other commercially available tests since it is readily soluble, membrane permeable, and converted by live cells intracellularly before transport into the extracellular tissue culture media. Because cell culture media is used, cells do not need to be lysed in this assay, saving time and cost while preserving the ability to perform other cellular tests in the same culture system. Please visit www.limrdevelopment.com for more information or to purchase a kit.